Latest News

Data from the Visonac® Phase IIb study were presented by Professor Ann-Marie Wennberg at the 15th Annual Euro PDT congress in Barcelona.

Oslo, Norway, 11 February 2016: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, announces its results for the fourth quarter and full year 2015.

Photocure will present its fourth quarter and full year 2015 report on Thursday 11 February 2016 at Hotel Continental, Oslo, Norway.

Videourology™, the online peer-reviewed complement to Journal of Endourology, has published a video on the USC clinical experience on 252 patients utilizing Blue Light Cystoscopy with Cysview.

Phase 2b results demonstrate a significant reduction in inflammatory lesions and a significant improvement in overall acne severity

New data on Blue Light Cystoscopy with Hexvix®/Cysview® to be presented during the 16th Annual Scientific Meeting in Urologic Oncology in Washington DC

In a news release November 17th, BioSyent announces that CYSVIEW® has been approved by Health Canada and BioSyent is now commencing the launch.

Introducing Hexvix® Blue Light Flexible Cystoscopy (BLFC) to the routine outpatient follow-up of bladder cancer patients in Sweden results in minimal financial impact with improved clinical outcomes and a reduction in health care resource utilization.

Oslo, Norway, 29 October 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, announces its results for the third quarter 2015.

Photocure will present its third quarter 2015 report on Thursday 29 October 2015 at Hotel Continental, Oslo, Norway.

Photocure announces today that the first patient has been enrolled in the Hexvix/Cysview Market Expansion Phase 3 study. The study will investigate the use of Hexvix/Cysview in the outpatient / surveillance setting and is designed to fulfill the FDA post marketing commitments. Results from the Phase 3 study are expected to be available in 2017.

Edison Group, an investment intelligence firm, has published a company research report about Photocure.

Oslo, September 22, 2015 – Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology today announces that a new patent for Cevira has been granted in Europe.

Oslo, Norway, 4 September, 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces that its partner and exclusive distributor, Juno Pharmaceuticals, has filed a marketing authorization application (MAA) for the registration of Hexvix in Australia. Hexvix is Photocure's flagship product used to aid in the diagnosis and management of bladder cancer.

A newly published article in BJUI shows that incorporating HAL- blue-light cystoscopy in trans-urethral bladder tumor resection for non-muscle invasive bladder cancer patients has no budget impact on the lifetime costs of managing bladder cancer patients in Sweden relative to white-light cystoscopy.

Kjetil Hestdal, President and Chief Executive Officer will present a Photocure company overview at the Pareto Securities' 6th Annual Health Care Seminar in Stockholm, on Friday, August 28, 2015 at 09:15.

Oslo, Norway, 19 August, 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies, announces today the appointment of BioSyent Pharma Inc. as their exclusive distributor for the commercialization of Cysview in Canada. Cysview®/Hexvix® is Photocure’s flagship product to aid in the diagnosis and management of bladder cancer.

Oslo, Norway, 13 August 2015: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies, announces its results for the second quarter and the first half year 2015.

Oslo, Norway, 10 August, 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today the approval of the Special Protocol Agreement (SPA) from the US FDA on the design of the Phase 3 clinical registration program for Cevira, which is in development for the treatment of high grade pre-cancerous lesions of the cervix. The SPA defines the size, design and analysis of clinical trials that will form the primary basis of approval.